Amneal Pharmaceuticals (AMRX) Income from Continuing Operations (2017 - 2026)

Amneal Pharmaceuticals' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 78000000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 216.84% year-over-year to 78000000.0; the TTM figure through Mar 2026 stood at 181315000.0 (up 459.27% YoY), while the FY2025 annual figure was 127933000.0, up 273.17% from the prior year.
• Income from Continuing Operations was 78000000.0 for Q1 2026 at Amneal Pharmaceuticals, up from 49573000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 78000000.0 in Q1 2026 to a low of 240081000.0 in Q2 2022.
• Historically, Income from Continuing Operations has averaged 10083588.24 across 5 years, with a median of 11757000.0 in 2024.
• Biggest YoY gain for Income from Continuing Operations was 1148.41% in 2023; the steepest drop was 1504.68% in 2023.
• A 5-year view of Income from Continuing Operations shows it stood at 5817000.0 in 2022, then sank by 1504.68% to 93344000.0 in 2023, then jumped by 77.78% to 20742000.0 in 2024, then soared by 339.0% to 49573000.0 in 2025, then soared by 57.34% to 78000000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 78000000.0 (Q1 2026), 49573000.0 (Q4 2025), and 18132000.0 (Q3 2025), per Business Quant data.